Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 5,328 matching trials from the live ClinicalTrials.gov search.
Not listed Phase 1 Interventional Accepts healthy volunteers

R4Power: An Online Resilience Program for Adolescents

NCT00641368
Conditions
Depression, Anxiety
Interventions
R4Power Program, Waitlist Control
Behavioral · Other
Lead sponsor
Swarthmore College
Other
Eligibility
11 Years to 15 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Swarthmore, Pennsylvania
Completed No phase listed Observational Accepts healthy volunteers

Psychedelics and Wellness Study (PAWS)

NCT04040582
Conditions
Depression, Anxiety, PTSD
Interventions
Not listed
Lead sponsor
WILD 5 Wellness
Other
Eligibility
18 Years to 100 Years
Enrollment
3,234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Austin, Texas
Conditions
Depression and Quality of Life, Sexual Violence, PTSD, Suicidal Ideation, Problem Drinking
Interventions
Empowerment self-defense training
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pine Ridge, South Dakota
Conditions
Major Depressive Disorder
Interventions
Problem Solving Therapy
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
San Francisco, California
Conditions
Depressive Disorder, Major
Interventions
Levomilnacipran ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
47
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 41 more
Conditions
Postpartum Depression
Interventions
Placebo, SAGE-547 90 μg/kg/h
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
32
States / cities
Chandler, Arizona • Rogers, Arkansas • Lemon Grove, California + 28 more
Conditions
Well-Being, Depressive Symptoms, Anxiety, Affect
Interventions
Multi-component Well-being Intervention, Study Skills
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 22 Years
Enrollment
294 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Cambridge, Massachusetts • Philadelphia, Pennsylvania
Completed Not applicable Interventional Results available

Environmental Treatment for Seasonal Affective Disorder (SAD)

NCT00139997
Conditions
Seasonal Affective Disorder
Interventions
Litebook treatment devices, Inactivated negative ion generator
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Major Depression
Interventions
Sertraline, Hypericum perforatum (St. John's wort)
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
12
States / cities
San Diego, California • Stanford, California • Torrance, California + 9 more
Conditions
Respiratory Depression, Obstructive Sleep Apnea
Interventions
Fentanyl
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
2 Years to 8 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cancer
Interventions
management of therapy complications, massage therapy, pain therapy, psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Results available

Open Treatment of Minocycline in Geriatric Depression

NCT01659320
Conditions
Depression
Interventions
Minocycline
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
55 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
White Plains, New York
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Analgesia, Ketamine, Peripheral Nervous System Agents, Central Nervous System Depressants, Neurotransmitter Agents, Anti-Inflammatory Agents, Physiological Effects of Drugs, Sensory System Agents, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal, Depressive Symptoms
Interventions
VTS-K
Drug
Lead sponsor
Theresa Jacob, PhD, MPH
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
25
States / cities
Scottsdale, Arizona • Encino, California • Los Alamitos, California + 21 more
Completed Phase 4 Interventional Results available

SSRI Effects on Depression and Immunity in HIV/AIDS

NCT02620150
Conditions
Depression, HIV, AIDS
Interventions
Escitalopram, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Infant, Newborn, Hypoxia, Brain, Hypoxia-Ischemia, Brain, Encephalopathy, Hypoxic-Ischemic, Hypoxic-Ischemic Encephalopathy, Ischemic-Hypoxic Encephalopathy
Interventions
Whole-body Cooling
Procedure
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 6 Hours
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more
Completed Not applicable Interventional Results available

Enhanced Medical Rehabilitation in Older Adults

NCT02114879
Conditions
Disabling Medical Events, Disabled, Depression
Interventions
Enhanced Medical Rehabilitation, Standard of Care Rehabilitation
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
St Louis, Missouri
Conditions
Treatment Resistant Depression
Interventions
Low Field Magnetic Stimulation (LFMS), Sham LFMS
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Birmingham, Alabama • New Haven, Connecticut • Atlanta, Georgia + 3 more
Conditions
Depression, Major Depressive Disorder, Persistent Depressive Disorder
Interventions
Transcranial Magnetic Stimulation (TMS)
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Disaster, PTSD, Adolescent Behavior, Trauma, Anxiety, Stress
Interventions
Sonoma Rises
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
13 Years to 17 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Completed Not applicable Interventional Accepts healthy volunteers

Contemplative Well-being Apps for the Workplace

NCT03452670
Conditions
Social Behavior, Depression, Inflammation
Interventions
Active Group, Waitlist Group
Behavioral · Other
Lead sponsor
Emory University
Other
Eligibility
21 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Depression, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Zoloft 50 mg, St. John's Wort 600 mg
Drug · Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
6
States / cities
Oakland, California • Rome, Georgia • Decatur, Illinois + 3 more
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL Negative, Blastic Phase Chronic Myelogenous Leukemia, Cancer Survivor, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Depression, Disseminated Neuroblastoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Psychosocial Effects of Cancer and Its Treatment, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma
Interventions
internet-based intervention, questionnaire administration, psychosocial assessment and care, assessment of therapy complications, management of therapy complications, fatigue assessment and management, counseling intervention
Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Other
Eligibility
18 Years and older
Enrollment
1,337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Seattle, Washington
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Behavior Brain Responses

NCT03964350
Conditions
Alcohol Drinking, Drinking Behavior, Physiological Effects of Drugs, Central Nervous System Depression
Interventions
Ethanol, Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 35 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois